Moderna to seek regulatory approval for Covid shot for very young children
Skip to main content
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
  • Epaper
  • More
    • Subscribe
    • COVID-19
    • Bangladesh
    • Splash
    • Videos
    • Games
    • Long Read
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
The Business Standard

Wednesday
July 06, 2022

Sign In
Subscribe
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
  • Epaper
  • More
    • Subscribe
    • COVID-19
    • Bangladesh
    • Splash
    • Videos
    • Games
    • Long Read
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
WEDNESDAY, JULY 06, 2022
Moderna to seek regulatory approval for Covid shot for very young children

Coronavirus chronicle

Reuters
23 March, 2022, 06:55 pm
Last modified: 23 March, 2022, 07:00 pm

Related News

  • BioNTech, Pfizer to start testing universal vaccine for coronaviruses
  • Children above 5 years to receive Covid jabs from July
  • S Korea approves first domestically developed Covid vaccine
  • Health minister calls for the registration of 5-12-year-old children for vaccination
  • Bangladesh gets another 4m Covid jabs from US

Moderna to seek regulatory approval for Covid shot for very young children

The Omicron variant of Covid-19 was predominant during Moderna's pediatric trial, and the drugmaker said two doses were around 38% effective in preventing infections in 2 to 5 year olds and 44% effective for children 6 months to under 2 years old

Reuters
23 March, 2022, 06:55 pm
Last modified: 23 March, 2022, 07:00 pm
Moderna has recently signed vaccine orders for 2022 worth $17 billion — which would make it one of the best-selling drugs in the world. Photo: Reuters
Moderna has recently signed vaccine orders for 2022 worth $17 billion — which would make it one of the best-selling drugs in the world. Photo: Reuters

Moderna Inc said on Wednesday it will ask regulators to authorize its Covid-19 vaccine in children younger than 6 years old based on data showing it generated a similar immune response to adults in its clinical trial.

The Omicron variant of Covid-19 was predominant during Moderna's pediatric trial, and the drugmaker said two doses were around 38% effective in preventing infections in 2 to 5 year olds and 44% effective for children 6 months to under 2 years old.

It said these figures were consistent with the lower effectiveness against Omicron seen in adults who had received two doses of its vaccine.

Moderna's vaccine could be the first authorized shot for children under the age of 5 in the United States, and many parents of young children have been waiting on a vaccine.

A rival shot made by Pfizer Inc and Germany's BioNTech SE  is authorized for use in children 5 and older. But their trial results for 2- to 4-year olds showed a weaker immune response than in adults, forcing the trial to be extended to test a third dose. Results are expected in April.

"Given the need for a vaccine against Covid-19 in infants and young children we are working with the US FDA and regulators globally to submit these data as soon as possible," Moderna Chief Executive Stephane Bancel said in a statement.

Dr. Jacqueline Miller, a top scientist at Moderna, told Reuters the company was "a couple of weeks away" from filing for authorization for the age group in the United States, Europe and elsewhere.

Generally well-tolerated 

It is not clear how many US parents will vaccinate their children in the age group. Only 27% of 5-11 year olds in the country are fully vaccinated, and Covid-19 is generally more mild in children than adults.

There were no severe cases in Moderna's pediatric trial for either vaccine or placebo partipicants.

Moderna said the shots, spaced four weeks apart, were generally well tolerated in the age group and the majority of side effects experienced were mild or moderate.

The dose size tested was 25 micrograms - a quarter of the dose that adults receive for each of their first two shots.

There have been some concerns about the size of the dose. By comparison, the dosage of Pfizer and BioNTech's vaccine - which uses similar messenger RNA technology - was 10 micrograms for 5 to 11 year olds. They are testing 3 microgram doses for children younger than 5.

"FDA did ask us to evaluate lower doses and we intend to do so," said Moderna's Miller. "However, we believe that the current data really support the dose selections that we have made in this age group... We are confident in the dose that we've chosen."

Moderna's vaccine is approved by the FDA for use in adults 18 and older. But it has yet to be approved for 6 to 17 year olds in the United States despite gaining approval for that age group in Australia, Canada and the European Union. The United Kingdom and Switzerland have allowed the vaccine to be used in 12-17 year olds.

US regulators have asked the company for more safety data and the FDA also said it needed additional time to evaluate the risk of a type of heart inflammation called myocarditis after vaccination in the age group, a rare side effect that has primarily affected young males.

Moderna says it plans to update its emergency use authorization filing in 12-17 year olds with more data, and has started the process for 6 to 11 year olds.

The company also said it plans to study a booster dose for all pediatric populations, including a booster that combines a vaccine designed to tackle the Omicron variant of the virus with its original Covid-19 vaccine.

Top News / World+Biz

Moderna / Moderna Vaccine / Covid vaccine

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • China-led trade bloc holds promise, with some caveats
    China-led trade bloc holds promise, with some caveats
  • British Chancellor of the Exchequer Rishi Sunak listens as British Prime Minister Boris Johnson addresses his cabinet on the day of the weekly cabinet meeting in Downing Street, London, Britain June 7, 2022. Leon Neal/Pool via REUTERS
    UK Johnson plunged into crisis as Sunak, health minister quits
  • Representational Image. Photo: Pixabay
    Load shedding the best course of action for now: Experts

MOST VIEWED

  • Illustration: Collected
    Omicron BA.5 most predominant Covid sub-variant in Bangladesh: icddr,b
  • A man helps his son to wear mask at Covid-19 test centre at KSRTC bus stand in Bengaluru.(PTI)
    India records 16,103 new Covid cases, 31 deaths in 24 hours
  • Former North Korean defectors living in South Korea, release balloons containing one dollar banknotes, radios, CDs and leaflets denouncing the North Korean regime, towards the north near the demilitarized zone which separates the two Koreas in Paju, north of Seoul January 15, 2014. REUTERS/Kim Hong-Ji/File Photo
    North Korea blames 'alien things' near border with South for Covid outbreak
  • People wearing protective face masks commute amid concerns over the new coronavirus disease (COVID-19) in Pyongyang, North Korea March 30, 2020, in this photo released by Kyodo. Picture taken March 30, 2020. Mandatory credit Kyodo/via REUTERS
    S Korea says leaflets sent by defectors unlikely to be cause of Covid in N Korea
  • Test tubes are seen in front of displayed Pfizer and Biontech logos in this illustration taken, May 21, 2021. Reuters: llustration
    BioNTech, Pfizer to start testing universal vaccine for coronaviruses
  • A woman holds a small bottle labelled with a "Coronavirus COVID-19 Vaccine" sticker and a medical syringe in this illustration taken October 30, 2020. REUTERS/Dado Ruvic/File Photo
    S Korea approves first domestically developed Covid vaccine

Related News

  • BioNTech, Pfizer to start testing universal vaccine for coronaviruses
  • Children above 5 years to receive Covid jabs from July
  • S Korea approves first domestically developed Covid vaccine
  • Health minister calls for the registration of 5-12-year-old children for vaccination
  • Bangladesh gets another 4m Covid jabs from US

Features

The OPEC+ group of 23 oil-exporting countries met virtually on Thursday. Photo: Bloomberg

OPEC+ did its job, but don’t expect it to disappear

17h | Panorama
Mirza Abdul Kader Sardar with AK Fazlul Haque, Chief Minister of Bengal, at Haque's reception at the Lion Cinema, Dhaka, 1941. Photo: Collected

Panchayats: Where tradition clings to survival

18h | Panorama
Illustration: TBS

Universal Pension Scheme: Has it been thought through?

20h | Panorama
Last month Swapan Kumar Biswas, the acting principal of Mirzapur United College, was forced to wear a garland of shoes for ‘hurting religious sentiments.’ Photo: Collected

Where do teachers rank in our society?

1d | Panorama

More Videos from TBS

Sheikh Kamal Business Incubator to be inaugurated at CUET Wednesday

Sheikh Kamal Business Incubator to be inaugurated at CUET Wednesday

9h | Videos
Tejgaon becoming uninhabitable for illegal rickshaw garages, truck stands

Tejgaon becoming uninhabitable for illegal rickshaw garages, truck stands

9h | Videos
50 companies plan to invest big in South

50 companies plan to invest big in South

10h | Videos
Alal, Dulal sell for Tk30 lakh

Alal, Dulal sell for Tk30 lakh

10h | Videos

Most Read

1
Photo: Collected
Africa

Uganda discovers gold deposits worth 12 trillion USD

2
TBS Illustration
Education

Universities may launch online classes again after Eid

3
Meet the man behind 'Azke amar mon balo nei'
Splash

Meet the man behind 'Azke amar mon balo nei'

4
Build Dhaka East-West Elevated Expressway, relocate kitchen markets: PM
Bangladesh

Build Dhaka East-West Elevated Expressway, relocate kitchen markets: PM

5
File Photo: BSS
Energy

India pulls out of LoC funding for part of Rooppur power transmission work

6
Illustration: TBS
Interviews

‘No Bangladeshi company has the business model for exporting agricultural product’

EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2022
The Business Standard All rights reserved
Technical Partner: RSI Lab
BENEATH THE SURFACE
Workers ready a passenger vessel with a fresh coat of paint to the deck ahead of the Eid-ul-Azha at a dockyard at Mirerbagh in South Keraniganj. The vessel getting the makeover plies the Bhandaria route and will take holidaying people from the city to their country homes. Eid will be celebrated on 10 June this year. The photo was taken on Monday. Photo: Mumit M

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net